Filing Analysis
Silence Therapeutics plc has entered into an underwriting agreement to conduct a public offering of 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS. The company expects to net approximately $164 million from the sale, which is intended to bolster its capital position.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 12.9 million new ADSs.
📋 Key Facts
- Underwriters: Jefferies LLC and Morgan Stanley & Co. LLC acting as representatives.
- Offering Size: 12,963,963 ADSs (each representing three ordinary shares).
- Pricing: $13.50 per ADS; Underwriter purchase price of $12.69 per ADS.
- Net Proceeds: Estimated at approximately $164 million (up to $188.7 million if over-allotment option is exercised).
- Closing Date: Expected August 13, 2026.
- Registration: Conducted under an effective shelf registration statement on Form S-3.
Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial evaluating divesiran for polycythemia vera (PV). The study met both primary and secondary endpoints, showing significant efficacy in hematocrit control and phlebotomy reduction.
🚩 Red Flags
- None identified in this clinical data announcement.
📋 Key Facts
- Phase 2 SANRECO trial was a 36-week, randomized, double-blind, placebo-controlled study.
- Primary endpoint (response rate) achieved: 88% for divesiran vs. 19% for placebo (p<0.0001).
- Divesiran dose groups showed response rates of 93.8% (Q6W) and 81.3% (Q12W).
- Secondary endpoint met: Mean phlebotomies reduced to 0.2 for divesiran vs. 2.1 for placebo.
- Safety profile was well tolerated with no new safety findings; injection site reactions were infrequent.
- Company expects to initiate a Phase 3 trial in the first half of 2027.
Silence Therapeutics plc has filed an 8-K to announce its financial and business results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release issued on August 10, 2026.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 10, 2026.
- The report contains results of operations and financial condition as per Item 2.02.
- Signed by Iain Ross, Interim Principal Executive Officer and Chairman of the Board.
Silence Therapeutics plc filed an amendment to its previous 8-K to disclose the specific terms of a separation agreement for former executive Craig Tooman, following his departure by mutual consent on December 14, 2025.
🚩 Red Flags
- Significant cash outflow for executive separation ($1.3M+ in total identified payments)
- Delayed disclosure/Amendment to a previous filing (8-K/A)
📋 Key Facts
- Separation Date: December 14, 2025
- Agreement effective date/disclosure date: July 10, 2026
- Salary continuation: $655,000 over 12 months
- Lump sum severance: $250,000
- Bonus payment (accrued for 2025): $283,746.03
- Legal fee reimbursement: $40,000
- Healthcare premium reimbursement: $46,896.48
- Tax provider fee reimbursement: up to $20,000
- Options vesting: Continued vesting through 45 days post-separation; acceleration upon change of control within 12 months.
Silence Therapeutics plc issued an updated corporate presentation via Item 7.01 to reflect recent business updates. This is a non-material disclosure intended for investor relations purposes and does not contain specific financial or structural changes.
📋 Key Facts
- The company released an updated corporate presentation on June 23, 2026.
- The update is hosted in the 'Investors' section of the company's website.
- The filing was signed by Iain Ross, acting as Interim Principal Executive Officer and Chairman.
Silence Therapeutics plc reported the results of its 2026 Annual General Meeting of Shareholders held on June 16, 2026. All nine resolutions presented to shareholders, including director re-appointments and auditor ratification, were duly passed.
📋 Key Facts
- The 2026 AGM took place on June 16, 2026.
- Rhonda Hellums and James Ede-Golightly were re-appointed as directors.
- PricewaterhouseCoopers LLP was ratified as both the U.S. independent registered public accounting firm and the U.K. statutory auditors for 2026.
- Shareholders approved the 2025 U.K. statutory annual accounts and reports.
- Executive compensation and the directors' remuneration report for 2025 were approved.
Silence Therapeutics plc issued a press release on June 11, 2026, presenting follow-up and quality-of-life data from the Phase 1 SANRECO study for divesiran in patients with polycythemia vera (PV) at the EHA 2026 Annual Congress.
📋 Key Facts
- The filing relates to the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6.
- The study included 21 phlebotomy-dependent patients with polycythemia vera (PV).
- Data was presented at the European Hematology Association (EHA) 2026 Annual Congress on June 11, 2026.
Silence Therapeutics entered into a new At-The-Market (ATM) sales agreement with Jefferies LLC, replacing its previous 2021 agreement. The company also updated its tax status, now stating it believes it was not a Passive Foreign Investment Company (PFIC) for the 2025 taxable year, reversing a prior assessment.
🚩 Red Flags
- Potential for shareholder dilution through the new ATM facility.
- Multiple 8-K items (1.01, 1.02, 8.01) reported in a single filing.
- Uncertainty remains regarding future PFIC status, which could still lead to adverse U.S. tax consequences.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on May 18, 2026.
- The new agreement replaces a prior ATM agreement dated October 15, 2021.
- Jefferies will receive a commission of up to 3.0% of gross sales proceeds.
- The ADSs will be issued under a new shelf registration statement on Form S-3 (File No. 333-295992).
- The company corrected its prior disclosure regarding PFIC status for the year ended December 31, 2025, now believing it was not a PFIC.
Silence Therapeutics plc reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The filing was signed by Iain Ross, who continues to serve as the Interim Principal Executive Officer.
🚩 Red Flags
- The company is operating under an Interim Principal Executive Officer (Iain Ross), indicating a lack of permanent top-tier management stability.
📋 Key Facts
- The company announced Q1 2026 financial results on May 7, 2026.
- The report was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Iain Ross is acting as both the Interim Principal Executive Officer and Chairman of the Board.
- The company is incorporated in England and Wales and maintains its principal executive offices in London.
Silence Therapeutics plc announced its fourth quarter and full year 2025 financial results on March 5, 2026. The company also released an updated corporate presentation detailing its business updates and pipeline progress.
🚩 Red Flags
- The company is currently led by an Interim Principal Executive Officer, indicating a pending permanent leadership transition
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025
- Updated corporate presentation was issued in March 2026
- Iain Ross is currently serving as Interim Principal Executive Officer and Chairman of the Board
- The filing includes Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure)
Silence Therapeutics plc filed an amendment to its 8-K to disclose compensation terms for interim CEO Iain Ross and committee appointments for new director James Ede-Golightly. The filing details a monthly cash stipend and significant equity grants for the interim leadership.
🚩 Red Flags
- Use of an 'interim' principal executive officer suggests leadership instability or a sudden vacancy in the permanent CEO role.
- Significant equity issuance (990,000 total options across two individuals) may lead to future dilution for existing shareholders.
📋 Key Facts
- Iain Ross appointed as interim principal executive officer effective December 14, 2025.
- Iain Ross to receive £25,000 monthly cash compensation for six months; thereafter on a month-to-month basis.
- Iain Ross granted options to purchase 900,000 ordinary shares, vesting over 12 months.
- James Ede-Golightly appointed to the Remuneration, Audit & Risk, and Nominations Committees effective December 18, 2025.
- James Ede-Golightly granted options to purchase 90,000 ordinary shares, vesting over 12 months.
Silence Therapeutics plc announced the appointment of its current CFO, Rhonda Hellums, to the Company's Board of Directors, effective December 18, 2025.
📋 Key Facts
- Rhonda Hellums appointed as Executive Director on December 18, 2025.
- Ms. Hellums currently serves as the Company’s EVP and CFO.
- The appointment is effective immediately for an initial term expiring at the end of the 2026 AGM.
- No additional compensation will be received for her service on the Board.
- She will not serve on any specific committees of the Board.
Silence Therapeutics plc announced the departure of its President and CEO, Craig Tooman, effective December 14, 2025. The Board has appointed Chairman Iain Ross as interim CEO and added James Ede-Golightly to the Board.
🚩 Red Flags
- Sudden departure of the President and CEO by 'mutual consent' often signals internal friction or strategic shifts.
- Leadership vacuum: The appointment of an interim CEO (the Chairman) suggests a transition period rather than a permanent succession plan being in place.
📋 Key Facts
- CEO Craig Tooman stepped down by mutual consent on December 14, 2025.
- Iain Ross (Chairman of the Board) appointed as interim Principal Executive Officer effective immediately.
- James Ede-Golightly appointed to the Board of Directors, with a term expiring at the 2026 AGM.
- The company is entering into a separation agreement with Mr. Tooman; terms are not yet disclosed.
- Compensation for the interim CEO and new director has yet to be determined.
Silence Therapeutics plc has filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- The filing is under Item 2.02 (Results of Operations and Financial Condition).
Silence Therapeutics plc announced the completion of patient enrollment for its SANRECO Phase 2 clinical study. The study evaluates divesiran for the treatment of polycythemia vera (PV).
📋 Key Facts
- Completion of enrollment in the SANRECO Phase 2 study.
- The study focuses on the drug candidate 'divesiran'.
- Target indication is polycythemia vera (PV).
- Announcement date: October 23, 2025.
Silence Therapeutics plc announced the immediate resignation of Director Michael Davidson from the Board and all committee positions on August 11, 2025. The departure is reportedly due to other professional commitments rather than any disagreement with management or the Board.
🚩 Red Flags
- Reduction in Board size from five to four directors may impact governance oversight/diversity of thought, though common in micro-caps.
📋 Key Facts
- Michael Davidson resigned from the Board effective August 11, 2025.
- Resignation includes membership on the Audit and Risk Committee, Remuneration Committee, and Science & Technology Committee.
- The Company reduced its Board size from five directors to four.
- Board Chairman Iain Ross was appointed to the Audit and Risk Committee to fill the vacancy.
- The resignation is stated to be due to other time commitments (CEO of NewAmsterdam Pharma Company N.V.) and not due to disagreements.
Silence Therapeutics plc announced its financial results for the second quarter ended June 30, 2025, via a press release. The filing serves as a formal notice of the earnings release and business highlights.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 7, 2025.
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
Silence Therapeutics plc held its 2025 Annual General Meeting (AGM) on June 26, 2025. Shareholders approved all thirteen proposed resolutions, including the re-appointment of directors and auditors.
📋 Key Facts
- The AGM was held on June 26, 2025.
- All 13 resolutions were passed by a poll vote.
- Directors David Lemus, Tim McInerney, Iain Ross, and Craig Tooman were all re-appointed.
- PricewaterhouseCoopers LLP was ratified as both U.S. independent registered public accounting firm and U.K. statutory auditors for the year ending December 31, 2025.
- Shareholders approved the adoption of new articles of association (Resolution 13).
- The company will hold non-binding advisory votes on executive compensation on an annual basis.
Silence Therapeutics plc issued an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: First Quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- Company is listed on Nasdaq under the symbol SLN.
Silence Therapeutics announced a planned retirement of director James Ede-Golightly and the simultaneous appointment of Tim McInerney to the Board. The changes include a transition in the chairmanship of the Remuneration Committee.
🚩 Red Flags
- None identified; departure is characterized as a retirement without disagreement with management.
📋 Key Facts
- James Ede-Golightly will retire from the Board following the 2025 AGM, anticipated for June 26, 2025.
- Ede-Golightly is stepping down as chair of the Remuneration Committee effective immediately; he remains a member until the 2025 AGM.
- Tim McInerney has been appointed to the Board, effective May 5, 2025.
- McInerney will serve as chair of the Remuneration Committee and a member of the Audit and Risk Committee.
- McInerney's compensation includes a $56,000 annual retainer and monthly vesting options for 48,000 ordinary shares over 36 months (initial grant) plus an annual grant of the same amount.
Silence Therapeutics plc announced its financial results for the fourth quarter and full year ended December 31, 2024. The filing includes a press release regarding earnings and a corporate presentation used during their earnings call.
📋 Key Facts
- Reported financial results for Q4 and Full Year 2024 on February 27, 2025.
- Issued a corporate presentation (Exhibit 99.2) to accompany the earnings call.
- The filing is primarily an announcement of quarterly/annual performance rather than a specific material event like a merger or bankruptcy.
Silence Therapeutics plc is transitioning its reporting status from a 'foreign private issuer' to a domestic issuer in the United States, effective January 1, 2025. This change requires more detailed and prompt SEC filings compared to their previous foreign private issuer status.
📋 Key Facts
- Effective January 1, 2025, the Company will file periodic reports as a U.S. domestic issuer rather than a foreign private issuer.
- Domestic reporting requirements are more detailed and extensive than those for foreign private issuers.
- The filing specifies disclosure channels including SEC filings, press releases, website, and social media (LinkedIn/X).
- Reported by CEO Craig Tooman on January 2, 2025.